

Docket No.: 20142/1201318-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
David Thomas et al.

Application No.: 09/773,866

Confirmation No.: 3286

Filed: February 1, 2001

Art Unit: 1644

For: CD40-BINDING APC-ACTIVATING
MOLECULES

Examiner: P. Gambel

INFORMATION DISCLOSURE STATEMENT (IDS)

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed after the mailing date of a Final Office Action or Notice of Allowance, whichever occurred first, but on or before payment of the Issue Fee (37 CFR 1.97(d)). Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered.

I hereby certify that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, no item of information

contained in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Our check in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) is enclosed. The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: October 12, 2005

Respectfully submitted,

By 
Lynn M. Russo
Registration No.: 54,071
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 527-7701 (Fax)
Attorneys/Agents For Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/773,866-Conf. #3286	
			Filing Date	February 1, 2001	
			First Named Inventor	David Thomas	
			Art Unit	1644	
			Examiner Name	P. Gambel	
Sheet	1	of	1	Attorney Docket Number	20142/1201318-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CD	Bjorck, P. et al.; "CD40 Antibodies Defining Distinct Epitopes Display Qualitative Differences In Their Induction Of B-Cell Differentiation"; <i>Immunology, Blackwell Scientific Publications</i> , GB, vol. 87, pages 291-295; 1996, XP002930984 ISSN: 0019-2805.		
	CA	Challa, A. et al., "Epitope-dependent Synergism And Antagonism Between CD40 Antibodies And Soluble CD40 Ligand For The Regulation Of CD23 Expression And IgE Synthesis In Human B Cells"; <i>Allergy (Copenhagen)</i> , vol. 54, no. 6, pages 576-583; June 1999 (1999-06). XP002276806 ISSN: 0105-4538.		
	CB	Dullforce, P. et al., "Enhancement Of T Cell-Independent Immune Responses In Vivo By CD40 Antibodies"; <i>Nature Medicine Nature Publishing Co., US</i> , vol. 4, no. 1, pages 88-91; January 1998 (1998-01). XP009026323 ISSN: 1078-8956.		
	CC	French, R. et al., "CD40 Antibody Evokes A Cytotoxic T-cell Response That Eradicates Lymphoma And Bypasses T-cell Help"; <i>Nature Medicine, Nature Publishing, CO, US</i> , vol. 5, no. 5, pages 548-553; May 1999 (1999-05). XP002159390 ISSN: 1078-8956.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

{W:2014211201318us100548974.DOC	XXXXXXXXXXXXXXXXXXXX	Date Considered	
Examiner			